CGRP Forum
Send to a colleague
Register  Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

Latest news from the CGRP Forum


Aimovig (erenumab) receives EU approval for migraine prevention

Aimovig (erenumab) has received EU approval for the prevention of migraine in adults experiencing four or more migraine days per month.

Read the full report here »


CGRP infusion provokes cluster headache

CGRP infusion has been shown to provoke cluster headache attacks in active-phase episodic cluster headache and in chronic cluster headache, but not in remission-phase episodic headache.

Read the full report here »


Phase 3 EVOLVE-2 study of galcanezumab published in Cephalgia

Published data from the Phase 3 EVOLVE-2 study (NCT02614196) have confirmed that monthly treatment with galcanezumab 120 mg and 240 mg reduced mean monthly migraine headache days.

Read the full report here »


Recurrent headache + asthma + allergic rhinitis may = migraine in adolescents

Clinicians should be on the look-out for adolescents presenting with recurrent headache who also have asthma and allergic rhinitis as the combination is highly suggestive of migraine.

Read the full report here »

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Amgen Novartis
© Copyright CGRP Forum 2018. Please click here to unsubscribe from future mailings.
‚Äč